Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

John Sarantopoulos; Alain C. Mita; Aiwu Ruth He; James Lloyd Wade; Chung-Tsen Hsueh; John Charles Morris; Albert C. Lockhart; David Quinn; Jimmy J. Hwang; James Walter Mier; Wenping Zhang; Claudine Wack; Jian Yin; Pierre-François Clot; Olivier Rixe

doi:10.1200/jco.2015.33.15_suppl.2538

Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

John Sarantopoulos
, Alain C. Mita
, Aiwu Ruth He
, James Lloyd Wade
, Chung-Tsen Hsueh
, John Charles Morris
, Albert C. Lockhart
, David Quinn
, Jimmy J. Hwang
, James Walter Mier
, Wenping Zhang
, Claudine Wack
, Jian Yin
, Pierre-François Clot
, Olivier Rixe

Hematology and Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	33
DOIs	https://doi.org/10.1200/jco.2015.33.15_suppl.2538
State	Published - May 20 2015

Disciplines

Pathology
Gastroenterology
Internal Medicine
Medicine and Health Sciences
Other Medical Specialties

Access to Document

10.1200/jco.2015.33.15_suppl.2538License: Unspecified

OpenUrl availability

Full text

Cite this

Sarantopoulos, J., Mita, A. C., He, A. R., Wade, J. L., Hsueh, C.-T., Morris, J. C., Lockhart, A. C., Quinn, D., Hwang, J. J., Mier, J. W., Zhang, W., Wack, C., Yin, J., Clot, P.-F., & Rixe, O. (2015). Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI). Journal of Clinical Oncology, 33. https://doi.org/10.1200/jco.2015.33.15_suppl.2538

@article{f3cf6ad21367477e94ac90a72935acc8,

title = "Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).",

author = "John Sarantopoulos and Mita, \{Alain C.\} and He, \{Aiwu Ruth\} and Wade, \{James Lloyd\} and Chung-Tsen Hsueh and Morris, \{John Charles\} and Lockhart, \{Albert C.\} and David Quinn and Hwang, \{Jimmy J.\} and Mier, \{James Walter\} and Wenping Zhang and Claudine Wack and Jian Yin and Pierre-Fran{\c c}ois Clot and Olivier Rixe",

note = "2538 Background: C studies excluded pts with HI. A Phase I dose-escalation study (NCT01140607) assessed the effect of HI on C PK and safety in pts with advanced solid tumors.",

year = "2015",

month = may,

day = "20",

doi = "10.1200/jco.2015.33.15\_suppl.2538",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

AU - Sarantopoulos, John

AU - Mita, Alain C.

AU - He, Aiwu Ruth

AU - Wade, James Lloyd

AU - Hsueh, Chung-Tsen

AU - Morris, John Charles

AU - Lockhart, Albert C.

AU - Quinn, David

AU - Hwang, Jimmy J.

AU - Mier, James Walter

AU - Zhang, Wenping

AU - Wack, Claudine

AU - Yin, Jian

AU - Clot, Pierre-François

AU - Rixe, Olivier

N1 - 2538 Background: C studies excluded pts with HI. A Phase I dose-escalation study (NCT01140607) assessed the effect of HI on C PK and safety in pts with advanced solid tumors.

PY - 2015/5/20

Y1 - 2015/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2538

U2 - 10.1200/jco.2015.33.15_suppl.2538

DO - 10.1200/jco.2015.33.15_suppl.2538

M3 - Article

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this